KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EPS (Weighted Average and Diluted) (2016 - 2026)

Idexx Laboratories has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at $3.09 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 17.94% year-over-year to $3.09; the TTM value through Dec 2025 reached $13.08, up 22.59%, while the annual FY2025 figure was $13.08, 22.59% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $3.09 at Idexx Laboratories, down from $3.4 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $3.63 in Q2 2025 and troughed at $1.56 in Q2 2022.
  • A 5-year average of $2.52 and a median of $2.48 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 82.17% in 2021 and later crashed 33.33% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $1.89 in 2021, then rose by 8.99% to $2.06 in 2022, then grew by 12.14% to $2.31 in 2023, then increased by 13.42% to $2.62 in 2024, then rose by 17.94% to $3.09 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for IDXX at $3.09 in Q4 2025, $3.4 in Q3 2025, and $3.63 in Q2 2025.